Can a diabetes pill protect hearts of dialysis patients?

NCT ID NCT05179668

Completed Disease control Sponsor: Medical University of Vienna Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the drug dapagliflozin (a diabetes medicine) against a placebo in 220 people on dialysis for kidney failure, with or without diabetes. The goal was to see if the drug could improve heart structure and be safe. Participants took the drug or placebo for a period, and doctors measured heart changes using ultrasound and blood tests.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome Hypertrophy, Left Ventricular kidney failure type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE DIABETES MELLITUS, TYPE 2 HEMODIALYSIS KIDNEY FAILURE LEFT VENTRICULAR HYPERTROPHY

Contacts and locations

Locations

Dialyseinstitut Dr. Waller

Feldbach, 8330, Austria
Dialyseinstitut Gießauf GmbH

Graz, Austria
Hanusch Krankenhaus

Vienna, 1140, Austria
Klinik Donaustadt

Vienna, 1220, Austria
Klinik Favoriten

Vienna, 1100, Austria
Klinik Landstraße

Vienna, 1030, Austria
Krankenhaus Hietzing

Vienna, 1130, Austria
Medical University of Vienna

Vienna, 1090, Austria
Wiener Dialysezentrum

Vienna, 1220, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.